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use, non-use, or cessation of lipid medications. The outcomes of this study correlate well with the results
of other research works. This single-practice study demonstrates the feasibility and potential of analysing
EHR data to address important clinical issues such as the relationship between all-cause mortality and
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Abstract: General practice electronic health record (EHR) data have significant potential for clinical
research. This study demonstrates the feasibility of utilising longitudinal EHR data analysis to
address clinically relevant outcomes and uses the relationship between lipid medication prescription
and all-cause mortality in the elderly as an exemplar for the validity of this methodology. EHR
data were analysed to describe the association of lipid medication use, non-use or cessation with
all-cause mortality in patients aged ≥75 years. Survival analysis with Cox regression was used to
calculate hazard ratios, which were adjusted for confounders. There was no significant difference in
all-cause mortality among patients according to their use, non-use, or cessation of lipid medications.
The outcomes of this study correlate well with the results of other research works. This single-practice
study demonstrates the feasibility and potential of analysing EHR data to address important clinical
issues such as the relationship between all-cause mortality and lipid medication prescription in
the elderly.
Keywords: hypolipidemic agents; family practice; electronic health records; survival analysis; aged;
aged 80 and over

1. Introduction
The substantial volume of data which exist in general practice electronic health records (EHRs)
presents opportunities for clinically relevant primary care research [1]. These research opportunities
are further enhanced because data are collected about patients, their health conditions and their
treatments within the environment in which they occur, thereby providing an important contextual
factor to the research [2]. The use of data recorded during routine care in primary care settings, rather
than collected under experimental conditions, is appropriate for the evaluation of comparative safety
or effectiveness of management [3]. The use of data collected from EHRs in pragmatic trials and
comparative effectiveness studies is an emerging research method [4]. Whilst randomised controlled
trials are important for informing clinicians of the ability of an intervention to make a difference in ideal
circumstances (efficacy), pragmatic trials are needed to measure the degree of benefit in a real-world
setting (effectiveness).
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Analysis of data collected routinely in the course of providing health care has a valuable place in
general practice research [5]. Data recorded contemporaneously can overcome recall bias [6]. By using
EHR data, the time and cost of additional data collection can be reduced [4,7]. While some data
in EHRs are of variable quality, other data are of high quality and have been benchmarked against
accepted general practice standards [8].
General practice data have the potential to address important health outcomes which are considered
by general practitioners (GPs). For example, the examination of the outcomes related to prescribing
patterns can inform future practice [9]. For instance, lipid-lowering medications such as statins, are
amongst the most frequently prescribed medications in Australia [10]. The risks associated with statins
increase with advancing age and with polypharmacy, which is common in older patients [11]. It is
important, therefore, to gain a better understanding about outcomes for elderly patients in relation to
the prescribing of these medications by general practitioners.
Currently in Australia, the Heart Foundation recommends the use of absolute cardiovascular risk
to guide decisions regarding the use of lipid-lowering therapy as a primary prevention [12]. The latest
guidelines suggest that all patients over 75 years of age can be assessed using the same risk algorithms
designed for those aged between 45 and 75. Notably, however, this recommendation is supported
by an expert consensus statement rather than literature describing well-designed trials [13]. Much of
the available literature suggests that there may be reductions in cardiovascular events when statins
are prescribed to the elderly as secondary prevention. However, the evidence is lacking for primary
prevention in this age group, and there is a paucity of evidence to suggest that statins influence
mortality [14–18].
Thus, there is a need for further research into the outcomes for elderly patients prescribed
lipid-lowering medications [18], and the research question is well-suited for primary care research
using a retrospective cohort design. The data required for such a study are accurately recorded in
general practice EHRs, and the potential to study a large number of subjects over a relatively long
period of time is easily realised [19]. The objective of this study was to demonstrate the feasibility of
using longitudinal EHR data for research and quality improvement, using the relationship between
lipid- lowering medications and all-cause mortality among elderly patients as an exemplar.
2. Materials and Methods
EHR data were drawn from a general practice in regional New South Wales, Australia. This
practice had, on average, nine GPs working during the study period. The EHR in use was Best Practice
Software™ [20], which uses a structured query language (SQL) database to organise relevant patient
data. An SQL query was developed (by the primary author, AH) to obtain de-identified data relating
to eligible patients.
Data were considered eligible if the patient attended the practice between 1 January 2007 and 31
December 2015 and was ‘active’ (defined as having a minimum of three visits in the two years prior
to study entry) [21]. Entry to the study was the latter of: 1 January 2007; the patient’s 75th birthday;
or one year after their first practice visit. The twelve-month lead-in period was determined, as patient
data including usual medications and past medical history are often not complete at the first visit but
added to the EHR at subsequent consultations.
Data were censored on 31 December 2015 for patients seen after this date, or on the date of their
last visit if not seen subsequent to 2015. For all data which were not censored, the study outcome was
the date of death recorded in the EHR.
The data collected included GP visit dates, dates of birth and death, prescription data, smoking
and marital status, and history of vascular disease or diabetes. Patients’ names and addresses were not
retrieved to ensure the data remained de-identified.
Patients were classified according to their history of lipid-lowering medication prescriptions.
‘Non-Users’ had no record of prescription for lipid-lowering medications, including prior to study
entry. ‘Users’ had been prescribed lipid-lowering medications, and their last recorded prescription
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was less than 12 months prior to death or censoring. ‘Stoppers’ had been prescribed lipid-lowering
medications but had not received a prescription for at least a year prior to death or censoring.
The all-cause mortality risks of these three groups of patients were compared after adjustment
for possible confounders using Cox regression, with non-users as the reference category. Possible
confounders which were adjusted for included age at study entry, number of prescriptions for any
medication per year (previously demonstrated as a proxy for multimorbidity) [22,23], smoking status
at the end of the study, marital status and the presence of ischaemic heart disease, cerebrovascular
disease, peripheral vascular disease or diabetes. We also undertook subgroup analyses stratified by
treatment for either primary prevention (i.e., no history of vascular disease) or secondary prevention
(patients with a history of one or more cardiovascular, cerebrovascular or peripheral vascular disease,
or diabetes). Data analysis was performed with SPSS [24] using two-tailed significance tests and a type
1 error rate of 0.05.
This research was approved by the Joint University of Wollongong and Illawarra Shoalhaven
Local Health District Human Research Ethics Committee (ref-2014/434).
3. Results
Data from a total of 1911 patients in the practice EHR database were eligible for study entry.
Of these, 324 (16.9%) were missing the smoking status, and 318 (16.6%) were missing the marital status.
In total, 431 (22.6%) were excluded due to missing data on one or more of the outcome variables, study
variables, or adjustment variables, giving an analytic data set of 1480 (77.4%) patients. The excluded
data had similar demographics and outcomes as the analytic data. The characteristics of the participants
are shown in Table 1.
Table 1. Characteristics of the study population.
Continuous Variables (Mean ± Standard Deviation)
Excluded
Cases

Complete
Cases

Non-User

Stopper

Continuous
User

81.36 (±6.12)
2.90 (±2.66)
19.87 (±24.93)

79.15 (±4.83)
4.62 (±3.06)
19.41 (±16.47)

80.54 (±5.48)
4.45 (±3.03)
18.62 (±17.71)

78.89 (±4.07)
5.63 (±2.83)
18.45 (±16.92)

77.65 (±4.07)
4.36 (±3.09)
20.78 (±14.59)

Excluded Cases

Complete
Cases

Non-User

Stopper

Continuous
User

Outcome
Death
Censored

66 (15.3%)
365 (84.7%)

265 (17.9%)
1215 (82.1%)

131 (19.8%)
529 (80.2%)

51 (20.0%)
204 (80.0%)

83 (14.7%)
482 (85.3%)

Gender
Male
Female

173 (40.2%)
257 (59.8%)

641 (43.3%)
839 (56.7%)

292 (44.2%)
368 (55.8%)

91 (35.7%)
164 (64.3%)

258 (45.7%)
307 (54.3%)

Smoking status
Non-smoker
Former smoker
Current smoker

40 (37.0%)
60 (56.5%)
7 (6.5%)

645 (43.6%)
780 (52.7%)
55 (3.7%)

279 (42.3%)
355 (53.8%)
26 (3.9%)

119 (46.7%)
124 (48.9%)
12 (4.7%)

247 (43.7%)
301 (53.3%)
17 (3.0%)

Marital status
Married or de facto
Single or separated
Widowed

41 (36.9%)
28 (25.2%)
42 (37.8%)

763 (51.6%)
159 (10.7%)
558 (37.7%)

314 (47.6%)
79 (12.0%)
267 (40.5%)

124 (48.6%)
20 (7.8%)
111 (43.5%)

325 (57.5%)
60 (10.6%)
180 (31.9%)

Cardiovascular disease
No
Yes

348 (80.7%)
83 (19.3%)

1062 (71.8%)
418 (28.2%)

573 (86.8%)
87 (13.2%)

154 (60.4%)
101 (39.6%)

335 (59.3%)
230 (40.7%)

Cerebrovascular disease
No
Yes

380 (88.2%)
51 (11.8%)

1226 (82.8%)
254 (17.2%)

570 (86.4%)
90 (13.6%)

195 (76.5%)
60 (23.5%)

461 (81.6%)
104 (18.4%)

Age at commencement of study (years)
Duration of follow-up (years)
Prescriptions per year

Categorical Variables (number, percentage)
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Table 1. Cont.
Continuous Variables (Mean ± Standard Deviation)
Excluded
Cases

Complete
Cases

Non-User

Stopper

Continuous
User

Peripheral vascular disease
No
Yes

421 (97.7%)
10 (2.3%)

1400 (94.6%)
80 (5.4%)

640 (95.5%)
30 (4.5%)

235 (92.2%)
20 (7.8%)

525 (92.9%)
40 (7.1%)

Diabetes mellitus
No
Yes

361 (83.8%)
70 (16.2%)

1163 (78.6%)
317 (21.4%)

584 (88.5%)
76 (11.5%)

173 (67.8%)
82 (32.2%)

406 (71.9%)
159 (28.1%)

Lipid medication use
Never
Ceased
Current

286 (66.4%)
54 (12.5%)
91 (21.1%)

660 (44.6%)
255 (17.2%)
565 (38.2%)

660 (100%)
-

255 (100%)
-

565 (100%)

The median duration of follow-up was 4.50 years. Overall, 6840 patient-years of data were
examined, and the outcome of death from any cause was measured in 265 patients (17.9%), with the
remainder being censored. The age at study entry ranged from 75 to 102 years, with the median of
78.02 years of age. The number of prescriptions for any medication ranged from 0 to 135 per year,
with a mean of 19.4 prescriptions per year. Statins comprised 95.0% of all lipid-lowering medications
prescriptions in this sample, with fibrates and ezetimibe making up the remainder. There were no
significant differences in outcomes for those prescribed statins compared with those prescribed other
lipid-lowering therapies.
Cox regression was used to calculate the hazard ratios (HR) of the variables, both unadjusted and
adjusted for the other variables examined. These HRs are shown in Table 2.
Table 2. Unadjusted and adjusted hazard ratios for all-cause mortality (HR, hazard ratio; REF, reference;
CI, confidence interval).
All Patients

Age
(per year)
Gender
Female
Male
Smoking status
Non-smoker
Former smoker
Current smoker
Marital status
Married or de facto
Single or separated
Widowed
Prescriptions per year
Cardiovascular disease
No
Yes

Primary Prevention

Secondary Prevention

Unadjusted
HR (95% CI)

Adjusted
HR (95% CI)

Unadjusted
HR (95% CI)

Adjusted
HR (95% CI)

Unadjusted
HR (95% CI)

Adjusted
HR (95% CI)

1.12
(1.09–1.14)

1.14
(1.12–1.17)

1.12
(1.08–1.15)

1.13
(1.08–1.17)

1.13
(1.09–1.16)

1.15
(1.11–1.19)

REF
1.30
(1.05–1.61)

REF
1.61
(1.22–2.11)

REF
1.13
(0.76–1.70)

REF
1.46
(0.92–2.32)

REF
1.38
(1.01–1.87)

REF
1.63
(1.20–2.40)

REF
0.92
(0.72–1.18)
2.23
(1.34–3.71)

REF
0.74
(0.57–0.96)
2.91
(1.71–4.95)

REF
0.84
(0.56–1.27)
3.50
(1.76–6.95)

REF
0.63
(0.40–1.00)
4.58
(2.16–9.75)

REF
0.93
(0.68–1.27)
1.41
(0.65–3.07)

REF
0.79
(0.56–1.10)
2.04
(0.91–4.59)

REF
0.64
(0.39–1.05)
1.08
(0.84–1.38)

REF
0.49
(0.29–0.81)
0.77
(0.57–1.02)

REF
0.58
(0.25–1.36)
1.15
(0.77–1.72)

REF
0.40
(0.16–0.99)
0.65
(0.40–1.06)

REF
0.69
(0.37–1.26)
1.06
(0.77–1.46)

REF
0.52
(0.28–0.97)
0.85
(0.59–1.22)

1.02
(1.02–1.03)

1.02
(1.02–1.03)

1.02
(1.01–1.03)

1.02
(1.01–1.03)

1.02
(1.01–1.03)

1.02
(1.01–1.03)

REF
1.33
(1.04–1.70)

REF
1.20
(0.91–1.58)

–

–

REF
1.25
(0.91–1.72)

REF
1.09
(0.76–1.57)
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Table 2. Cont.
All Patients

Cerebrovascular disease
No
Yes
Peripheral vascular disease
No
Yes
Diabetes mellitus
No
Yes
Lipid medication use
Current
Never
Ceased

Unadjusted
HR (95% CI)

Adjusted
HR (95% CI)

REF
1.24
(0.94–1.65)

REF
1.16
(0.87–1.55)

REF
1.25
(0.82–1.90)

REF
1.15
(0.75–1.78)

REF
0.92
(0.68–1.24)

REF
0.92
(0.67–1.26)

REF
1.32
(1.01–1.74)
1.01
(0.71–1.42)

REF
0.97
(0.70–1.33)
0.87
(0.61–1.25)

Primary Prevention
Unadjusted
HR (95% CI)

–

Adjusted
HR (95% CI)

–

–

–

–

–

REF
1.57
(0.94–2.64)
0.92
(0.43–1.94)

REF
0.91
(0.57–1.57)
0.59
(0.26–1.30)

Secondary Prevention
Unadjusted
HR (95% CI)

Adjusted
HR (95% CI)

REF
1.13
(0.82–1.55)

REF
1.09
(0.76–1.55)

REF
0.56
(0.74–1.75)

REF
1.18
(0.75–1.84)

REF
0.78
(0.56–1.08)

REF
0.89
(0.62–1.28)

REF
1.44
(1.01–2.05)
1.05
(0.71–1.56)

REF
0.97
(0.66–1.45)
0.92
(0.62–1.38)

Increasing age, male gender, current smoking and increasing numbers of prescriptions per year
were all associated with a statistically significant increased hazard for all-cause mortality. There was
no increased risk of mortality for patients who had their lipid medication ceased nor for those patients
who had never been prescribed lipid medication. This was true also for the subset of patients with
a history of vascular disease or diabetes, whose lipid medications could be classed as secondary
prevention. A trend for improved survival among primary prevention patients who stopped taking
lipid medication relative to continuous users did not achieve statistical significance.
Adjusted Kaplan–Meier curves shown in Figure 1 demonstrate the non-significant differences in
survival for the different groups based on lipid medication use.
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Discussion
4. 4.Discussion
Thisstudy
studydesign
designwas
wasable
able
address
importantprimary
primarycare
careclinical
clinicaloutcomes
outcomesusing
usingdata
datarecorded
This
toto
address
important
recorded contemporaneously during the provision of routine care. The examination of EHR data
contemporaneously during the provision of routine care. The examination of EHR data using survival
using survival analysis to achieve a longitudinal design offers a novel approach and carries
analysis to achieve a longitudinal design offers a novel approach and carries significant advantage
significant advantage over cross-sectional studies when examining the outcomes of differing
over
cross-sectional studies when examining the outcomes of differing treatment decisions [25].
treatment decisions [25].
Our
to demonstrate
demonstrateany
anyincreased
increased
of death
associated
cessation of
Ourresearch
researchwas
was unable
unable to
riskrisk
of death
associated
with with
cessation
lipid
medications
in
elderly
patients.
We
were
unable
to
find
other
research
specifically
examining
of lipid medications in elderly patients. We were unable to find other research specifically examining

mortality in older patients in relation to lipid therapy cessation. The separation of the Kaplan–Meier
curves between stoppers and other lipid medication groups is interesting and supports powering
future EHR studies for further analysis.
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Although we found no survival advantage in patients treated for secondary prevention, other
studies examining mortality and lipid therapy in older patients found a small survival advantage in
elderly patients with cardiovascular disease [26] or with diabetes [27], suggesting further subgroup
analysis may be beneficial.
Our research is consistent with other research using prospective data which also shows no survival
advantage when lipid medications are used for primary prevention in the elderly [17,27,28].
Known risk factors such as increasing age, male gender, prescription counts and current smoking
were associated with increased hazard for all-cause mortality. Despite incomplete smoking data in the
eligible patients, our research demonstrated an adjusted hazard ratio of 2.9 which correlates well with
the results of another study which demonstrated relative mortality rates in older smokers of 1.2 to
3.4 [29]. This suggests that the study design can identify such risk when present.
A limitation of this study is that the use of data from a single practice limits the generalisability of
the results. A wider data collection with greater numbers and broader geographical and socioeconomic
spread will enable a more extensive application of the results. The data were originally recorded to
facilitate clinical care rather than for research purposes. No information is known about the reasons for
ceasing lipid medication or even not prescribing it. If patients with less severe disease are more likely
to have medication ceased, it may bias the results toward greater survival in this group. Conversely,
if lipid medications are ceased because the clinician perceives a shortened lifespan due to comorbidities,
the bias would be reversed. Missing data regarding smoking and marital status have the potential to
bias the results. Further examination of the patients excluded due to missing data will be necessary
on a larger sample size to more accurately determine if a bias exists. The duration of confounders
such as a diagnosis of diabetes or vascular disease was not measured, nor was the duration or type of
lipid medications quantified in our study. Further analysis of these factors in future studies would be
interesting and suited to this study design.
Analysis of EHRs has been employed to examine the relationship of statins with mortality in the
elderly in a large study in Spain [27]. Further research using a study design similar to that of our study
but with a larger volume and spread of data will be helpful to make comparisons with the existing
international research. Additionally, further research using this methodology has the potential to
address a common fear of deprescribing lipid medications to elderly patients [30]. This study design
has demonstrated the validity of longitudinal analysis of EHRs at a practice level and offers a low-cost
method of examining real-world primary care data to address important clinical questions.
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writing—review and editing, A.J.H., J.M., D.M., A.B.
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